产品
编 号：F752183
分子式：C20H17N9O2S
分子量：447.47
分子式：C20H17N9O2S
分子量：447.47
产品类型
规格
价格
是否有货
结构图
CAS No: 2410402-88-7
产品详情
生物活性：
CDK2-IN-12 (compound 10b) is a potent CDK2 inhibitor, with an IC50 of 11.6 μM. CDK2-IN-12 inhibits hCA (carbonic anhydrase) isoforms I, II, IX and XII, with KI values of 3534, 638.4, 44.3, and 48.8 nM. CDK2-IN-12 shows anticancer activity.
体外研究：
CDK2-IN-12 (compound 10b) exerts outstanding anti-proliferative activity against leukemia (CCRF-CEM, HL-60TB, K-562 and MOLT-4), non-small cell lung cancer (HOP-92), colon cancer (COLO 205, HCT-116 and SW-620), renal (ACHN) and breast (MDA-MB-468) cell lines with GI% (percentage growth inhibition) ranging from 80 to 100%. CDK2-IN-12 displays much enhanced growth inhibitory activity, under normoxic and hypoxic conditions, against MDA-MB-468 (IC50 = 1.37 ± 0.07 and 3.03 ± 0.11 μM) than MCF-7 cells (IC50 = 6.80 ± 0.17 and 15.10 ± 0.82 μM).
CDK2-IN-12 (compound 10b) is a potent CDK2 inhibitor, with an IC50 of 11.6 μM. CDK2-IN-12 inhibits hCA (carbonic anhydrase) isoforms I, II, IX and XII, with KI values of 3534, 638.4, 44.3, and 48.8 nM. CDK2-IN-12 shows anticancer activity.
体外研究：
CDK2-IN-12 (compound 10b) exerts outstanding anti-proliferative activity against leukemia (CCRF-CEM, HL-60TB, K-562 and MOLT-4), non-small cell lung cancer (HOP-92), colon cancer (COLO 205, HCT-116 and SW-620), renal (ACHN) and breast (MDA-MB-468) cell lines with GI% (percentage growth inhibition) ranging from 80 to 100%. CDK2-IN-12 displays much enhanced growth inhibitory activity, under normoxic and hypoxic conditions, against MDA-MB-468 (IC50 = 1.37 ± 0.07 and 3.03 ± 0.11 μM) than MCF-7 cells (IC50 = 6.80 ± 0.17 and 15.10 ± 0.82 μM).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备